BioSpace Global Roundup, Oct. 15
The Pharma Data
OCTOBER 14, 2020
AOP anticipates new opportunities in Austria as a hub for research and business. Priothera will use the funds to progress the clinical development of mocravimod, a modulator of sphingosine 1 phosphate (S1P) receptors, to enhance the curative potential of allogeneic hematopoietic stem cell transplantation (HSCT) for treating AML.
52 
Let's personalize your content